Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zentiva sets strategy as it starts out alone

Executive Summary

Ensuring that Zentiva has the necessary strategy, skills, competencies, capabilities and people to operate independently as a “leading European generics player” is a key priority, the company’s head, Patrick Aghanian, told Generics bulletin as the firm started life as an independent company under the ownership of private-equity investor Advent International.

You may also be interested in...

Sanofi Declines Despite Moving Past Zentiva Comparison

After seemingly stabilizing late last year, Sanofi has seen its generics sales once again drop in the first quarter of 2020, despite moving past unfavorable prior-year comparisons with the Zentiva generics business which the company divested in 2018.

Sanofi’s Generics Sales Stabilize Post-Zentiva

Reporting its fourth-quarter and full-year 2019 results, Sanofi saw an overall drop in generics sales following 2018’s divestment of Zentiva in Europe but enjoyed consistent turnover in emerging markets. Moreover, fourth-quarter generics turnover showed a stabilization of the business once the Zentiva comparison is removed.

Global Top Three Trade Places As Going Gets Tough, Especially In The US

Mylan has moved up to become the world’s leading generics, biosimilars and OTC player, according to Generics Bulletin’s newly compiled global rankings. Sandoz has surpassed troubled Teva into second spot, but is set to surrender that position once it sells its US solid-dose and dermatology business to India’s Aurobindo, which has already moved into the global top 10.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts